GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-br...
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S....
- AVITA Medical, Inc., a leading therapeutic acute wound care company,announced it has received the CE Mark under the European Union Medical Device Regul...
The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored in Düsseldorf with the Innovation Award 2025 of the State ...
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
-IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, inaugurated its expanded LMR Naturals site in Grasse fo...
World’s #1 Selling Contact Lens Brand ACUVUE® brings pioneering innovation for astigmatic patients, providing visual clarity and comfort Johns...
Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 mill...
CrystalsFirst GmbH, a leader in high-performance structural biology services, and NexMR AG, a pioneer in ultrafast NMR screening, announ...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of...
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LD...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...
© 2025 Biopharma Boardroom. All Rights Reserved.
